Bristol-Myers Squibb (BMY) investors will be focused on the trajectory of Cobenfy, its schizophrenia therapy, on its first full quarter on the market, UBS said in a note emailed Friday.
The brokerage believes the company will have some insight into the drug's indication expansion, based on the phase 3 study of adjunctive schizophrenia. The results from the trial are expected in Q2.
On the earnings front, UBS said it was estimating Q1 EPS of $1.52, in line with expectations.
In its note, UBS highlighted a number of headwinds heading into the earnings, such as about $500 million in destocking, Medicare Part D redesign, and erosion of the company's legacy portfolio. But, these headwinds were already baked into consensus expectations.
Consensus for Eliquis and Revlimid sales could be too low, UBS said, as data from IQVIA indicated that prescriptions for both medicines was strong. It was forecasting Q1 Eliquis sales of $3.40 billion, ahead of consensus' $3.34 billion, and Revlimid sales at $838 million, also above the consensus' $802 million.
All in, UBS said its total sales estimate for the quarter was 0.8% above consensus.
The firm slashed its price target for Bristol-Myers to $54 from $60, with a neutral rating.
Price: 50.44, Change: -0.02, Percent Change: -0.04
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。